Testosterone Undecanoate Soft Gel Capsule Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral delivery methods for testosterone undecanoate face challenges such as poor bioavailability, high dosing frequency, and potential liver damage due to first-pass metabolism, along with enzyme induction leading to drug-drug interactions.
Innovation Solution
Development of pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate with a solubilizer, where the testosterone undecanoate loading is between 14 wt% to 35 wt%, allowing for a single daily dose of 350 mg to 650 mg, which provides a serum testosterone Cmax to Cavg ratio of 2.7 or less, and a method for titrating doses based on serum concentration to maintain target levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If testosterone undecanoate is administered orally, then patient compliance and convenience are improved, but bioavailability is poor and dosing frequency must be high
Solution Approach 1:
The patent changes the chemical parameters of testosterone by converting it to testosterone undecanoate, an ester derivative with improved oral bioavailability. This parameter change in the molecular structure allows the compound to withstand first-pass metabolism better, thereby improving reliability of oral delivery while maintaining ease of administration.
Solution Approach 2:
The patent formulates testosterone undecanoate as a soft gel capsule containing a eutectic mixture of testosterone undecanoate and a lipid carrier (such as medium-chain triglycerides). This composite material system enhances dissolution and absorption, improving bioavailability while maintaining the convenient oral dosage form.
2Loss of time
If testosterone undecanoate loading is increased in the capsule, then dosing frequency is reduced, but serum testosterone levels become unstable
Solution Approach 1:
The patent creates a dynamic release system where the soft gel capsule formulation with eutectic mixture provides controlled dissolution and absorption of testosterone undecanoate. This dynamic system releases the hormone at a rate that maintains stable serum levels over time, preventing both peaks and troughs that would occur with simple high-dose administration.
Solution Approach 2:
The formulation ensures continuous absorption and release of testosterone throughout the dosing interval. The soft gel matrix provides sustained release characteristics, maintaining therapeutic levels continuously rather than allowing intermittent spikes and drops, thereby reducing dosing frequency while preserving stability.
3Ease of operation
If testosterone undecanoate is administered orally, then convenience is improved, but liver damage and enzyme induction occur
Solution Approach 1:
The patent uses a lipid carrier and solubilizing agents as intermediaries to facilitate the absorption of testosterone undecanoate through the gastrointestinal tract. This intermediary system reduces the direct metabolic burden on the liver by improving intestinal absorption efficiency, thereby minimizing first-pass metabolism and associated hepatic toxicity while maintaining oral convenience.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enhances bioavailability, reduces the frequency of dosing, and minimizes liver-related issues by achieving stable serum testosterone levels within a therapeutic range, improving the safety and efficacy of testosterone therapy for hypogonadism treatment.
Implementation Method 1
The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total weight of the capsule fill
Data Source
AI summary
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.